These findings provide a foundation for the development of Clec7a-targeted therapies aimed at slowing the progression of Alzheimer’s disease and other neurodegenerative disorders characterized by synaptic dysfunction. The gene discussed is CLEC7A; the disease is Alzheimer disease.